Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BCDA 
Biocardia Inc (BCDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BCDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -84.69% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.37M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.81 | 52 Weeks Range 1.62 - 3.26 | Updated Date 08/29/2025 |
52 Weeks Range 1.62 - 3.26 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.5 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -222.28% | Return on Equity (TTM) -737.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11135399 | Price to Sales(TTM) 3089.53 |
Enterprise Value 11135399 | Price to Sales(TTM) 3089.53 | ||
Enterprise Value to Revenue 3111.7 | Enterprise Value to EBITDA -3.16 | Shares Outstanding 5801220 | Shares Floating 4328583 |
Shares Outstanding 5801220 | Shares Floating 4328583 | ||
Percent Insiders 18.98 | Percent Institutions 5.25 |
Upturn AI SWOT
Biocardia Inc
Company Overview
History and Background
BioCardia, Inc. was founded in 1998. It focuses on developing and commercializing cell-based therapies for cardiovascular diseases. The company has evolved from initial research to clinical trials, seeking FDA approval for its lead product, CardiAMP.
Core Business Areas
- Cardiovascular Cell Therapies: Developing and commercializing autologous cell therapies, primarily for the treatment of heart failure and ischemic diseases.
- CardiAMP Cell Therapy System: A system that utilizes a patient's own bone marrow cells to promote heart repair and regeneration.
- Clinical Trials and Research: Conducting clinical trials to demonstrate the safety and efficacy of their therapies and expand their applications.
Leadership and Structure
BioCardia is led by a management team with experience in biotechnology and cardiovascular medicine. The organizational structure includes departments for research and development, clinical trials, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- CardiAMP Cell Therapy System: BioCardia's lead product candidate. It uses a patient's own bone marrow cells to potentially improve heart function in patients with chronic heart failure due to ischemic heart disease. Market share is not currently measurable due to the product being in late-stage clinical trials and not yet commercially available. Competitors include companies developing similar cell therapies and traditional heart failure treatments.
- Morpho Vascular Guiding Catheter: A delivery system for minimally invasive procedures, which also serves as a revenue source while waiting for the CARDIAMP commercial launch. Competitors include major medical device companies selling guiding catheters.
Market Dynamics
Industry Overview
The cardiovascular cell therapy market is growing, driven by the increasing prevalence of heart failure and the need for novel treatments. Regulatory hurdles and manufacturing complexities are key challenges.
Positioning
BioCardia is positioned as a leader in autologous cell therapies for cardiovascular diseases, particularly heart failure. Its competitive advantage lies in its CardiAMP system and personalized approach.
Total Addressable Market (TAM)
The TAM for heart failure therapies is substantial, estimated at billions of dollars. BioCardia aims to capture a significant share through its CardiAMP therapy, targeting patients who do not respond adequately to traditional treatments.
Upturn SWOT Analysis
Strengths
- Proprietary CardiAMP technology
- Personalized approach to cell therapy
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- High clinical trial costs
- Regulatory uncertainty
- Limited commercialization experience
- Reliance on successful clinical trial outcomes
Opportunities
- Expanding CardiAMP applications to other cardiovascular diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to FDA approval
- Increasing awareness of cell therapy benefits
Threats
- Competition from established heart failure treatments
- Adverse clinical trial results
- Changes in regulatory landscape
- Difficulty securing financing
Competitors and Market Share
Key Competitors
- MESO
- CRBP
- ATHX
Competitive Landscape
BioCardia faces competition from companies developing cell therapies, gene therapies, and traditional heart failure treatments. Its competitive advantage lies in its autologous approach, which may reduce the risk of immune rejection.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of the CardiAMP program through clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and FDA approval of CardiAMP. Analyst estimates vary widely, reflecting the inherent risk in biotech investing.
Recent Initiatives: Recent initiatives include completing enrollment in key clinical trials and securing additional funding to support operations.
Summary
BioCardia is a high-risk, high-reward biotech company focused on developing cell therapies for heart failure. Its CardiAMP system shows promise, but success hinges on positive clinical trial results and regulatory approval. The company needs to manage its cash carefully and navigate a competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- ClinicalTrials.gov
- Analyst reports (when accessible)
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary. Financial metrics are based on publicly available data and may not be entirely up-to-date.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biocardia Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2008-03-14 | CEO, President & Director Dr. Peter A. Altman Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.biocardia.com |
Full time employees 17 | Website https://www.biocardia.com | ||
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.